Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 14/20 | 0.55 |
| ▸ | TACR3 | P29371 | 14/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.55 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442143 | 0.91 | TACR2 (0.66) | TACR2TACR3OPRM1TRPV4CYP2C9 | |
| SCHEMBL6201151 | 0.90 | TACR2 (0.45) | TACR2TACR3OPRM1TRPV4CYP2C9 | |
| SCHEMBL5454432 | 0.83 | DHODH (0.54) | — | |
| SCHEMBL5438071 | 0.80 | TACR2 (0.60) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5945420 | 0.80 | TACR2 (0.82) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5418578 | 0.80 | TACR2 (0.56) | TACR2TACR3OPRM1TRPV4CYP2C9 | |
| SCHEMBL5423041 | 0.80 | TACR2 (0.56) | TACR2TACR3OPRM1TRPV4CYP2C9 | |
| SCHEMBL5908809 | 0.80 | TACR2 (0.69) | TACR2TACR3OPRM1TRPV4IDO1 | |
| SCHEMBL5455843 | 0.78 | TACR2 (0.57) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL6792050 | 0.78 | CYP2C9 (0.60) | TACR2TACR3OPRM1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | TACR2 22/4885TACR3 45/4885OPRM1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.